Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening.

NCT04614493 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04614493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening.
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Unknown status
Start date
September 11, 2021
Completion date
March 31, 2024
Enrollment
66 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

eligible for the standard of care including concurrent temoradiation and adjuvant temozolomide, initial radiological diagnosis compatible with newly diagnosed glioblastoma (idh wild-type), initial radiological diagnosis eligible for tumor resection